What is this study about?
This trial is testing an investigational drug candidate, nelotanserin, to determine if it is safe and effective in treating visual hallucinations in people with Lewy body dementia.
What is involved?
The study begins with a double-blind, placebo controlled phase, which means neither the researcher nor the person in the study will know who is getting the investigational drug candidate or a placebo. Participants who complete the study may be eligible for an open-label extension in which all participants will receive nelotanserin.
Participants in this study will attend an initial screening visit plus another 7 visits over approximately 18 weeks. Transportation assistance to and from study visits may be available.
Who can participate?
An individual with LBD may be able to take part in the trial if he/she*:
- Is at least 50 years old
- Has been diagnosed with dementia with Lewy bodies (DLB) or Parkinson’s disease dementia (PDD)
- Has frequent visual hallucinations
*additional eligibility criteria apply
Axovant Sciences, Ltd.
Still have questions?
For more information about this clinical trial, please contact Axovant Sciences at (833) 600-0350.